Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

JAK1 activates STAT3 activity in non-small-cell lung cancer cells and IL-6 neutralizing antibodies can suppress JAK1-STAT3 signaling.

Molecular cancer therapeutics - 1 Mar 2011

Song Lanxi, Rawal Bhupendra, Nemeth Jeffrey A, Haura Eric B

Abstract excerpt

Members of the signal transducer and activator of transcription (STAT) family of transcription factors are potential targets for the treatment and prevention of cancers including non-small-cell lung cancer. STAT proteins can be phosphorylated and activated by diverse upstream kinases including cytokine receptors and tyrosine kinases. We examined STAT protein activation in lung cancer cell lines including those...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Monoclonal
Share to Antibodies, Neutralizing

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Immunoblotting

Share to Immunoprecipitation

Share to Interleukin-6

Share to Janus Kinase 1

Share to Mice, Nude

Share to STAT3 Transcription Factor

Source

Open in PubMed Open full text

Identifiers

PMID: 21216930
DOI: 10.1158/1535-7163.MCT-10-0502
PMCID: PMC4084653

Genes

STAT3
EGFR
JAK1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

JAK1 activates STAT3 activity in non-small-cell lung cancer cells and IL-6 neutralizing antibodies can suppress JAK1-STAT3 signaling.PMID 21216930Read ↗

Targeting the Interleukin-6/Jak/Stat Pathway in Human MalignanciesSemantic proximity Read ↗

The JAK/STAT3 axis: A comprehensive drug target for solid malignancies.Semantic proximity Read ↗

Signal transducer and activator of transcription 3 is required for the oncogenic effects of non-small-cell lung cancer-associated mutations of the epidermal growth factor receptor.Semantic proximity Read ↗

Small Molecule Inhibitors of STAT3 for Cancer TherapySemantic proximity Read ↗

Novel activators and small-molecule inhibitors of STAT3 in cancerSemantic proximity Read ↗

Strategies and Approaches of Targeting STAT3 for Cancer TreatmentSemantic proximity Read ↗

Oncogenic STAT Transcription Factors as Targets for Cancer Therapy: Innovative Strategies and Clinical TranslationSemantic proximity Read ↗

STAT3 is activated by JAK2 independent of key oncogenic driver mutations in non-small cell lung carcinoma.Semantic proximity Read ↗

Role of STAT3 in lung cancerSemantic proximity Read ↗

Successful Treatment of Interstitial Lung Disease in STAT3 Gain-of-Function Using JAK InhibitorsSemantic proximity Read ↗

STAT3 inhibition, a novel approach to enhancing targeted therapy in human cancersSemantic proximity Read ↗

STAT3 Signaling in CancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.